Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))

Alessandro Armuzzi; Paolo Gionchetti; Marco Daperno; Silvio Danese; Ambrogio Orlando; Maria Lia Scribano; Maurizio Vecchi; Fernando Rizzello; Sandro Ardizzone; Alessandro Armuzzi; Fabiana Castiglione; Silvio Danese; Marco Daperno; Massimo Fantini; Gionata Fiorino; Giuseppe Frieri; Paolo Gionchetti; Luca Neri; Ambrogio Orlando; Mariabeatrice Principi; Fernando Rizzello; Maria Lia Scribano; Giacomo Carlo Sturniolo; Maurizio Vecchi; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group

doi:10.1016/j.dld.2016.06.015

Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))

Alessandro Armuzzi, Paolo Gionchetti, Marco Daperno, Silvio Danese, Ambrogio Orlando, Maria Lia Scribano, Maurizio Vecchi, Fernando Rizzello, Sandro Ardizzone, Alessandro Armuzzi, Fabiana Castiglione, Silvio Danese, Marco Daperno, Massimo Fantini, Gionata Fiorino, Giuseppe Frieri, Paolo Gionchetti, Luca Neri, Ambrogio Orlando, Mariabeatrice PrincipiFernando Rizzello, Maria Lia Scribano, Giacomo Carlo Sturniolo, Maurizio Vecchi, GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the last paragraph of Section 1, the sentence “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]” should be replaced with: “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]”. Mariabeatrice Principi, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, should have been listed in Appendix A (Members of the GIVI Study Group).

Original language	English
Pages (from-to)	1103
Number of pages	1
Journal	Digestive and Liver Disease
Volume	48
Issue number	9
DOIs	https://doi.org/10.1016/j.dld.2016.06.015
Publication status	Published - Sept 1 2016

ASJC Scopus subject areas

Medicine(all)
Hepatology
Gastroenterology

Access to Document

10.1016/j.dld.2016.06.015

Cite this

Armuzzi, A., Gionchetti, P., Daperno, M., Danese, S., Orlando, A., Scribano, M. L., Vecchi, M., Rizzello, F., Ardizzone, S., Armuzzi, A., Castiglione, F., Danese, S., Daperno, M., Fantini, M., Fiorino, G., Frieri, G., Gionchetti, P., Neri, L., Orlando, A., ... GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group (2016). Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370)). Digestive and Liver Disease, 48(9), 1103. https://doi.org/10.1016/j.dld.2016.06.015

Erratum : Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370)). / Armuzzi, Alessandro; Gionchetti, Paolo; Daperno, Marco et al.

In: Digestive and Liver Disease, Vol. 48, No. 9, 01.09.2016, p. 1103.

Research output: Contribution to journal › Comment/debate › peer-review

Armuzzi, A, Gionchetti, P, Daperno, M, Danese, S, Orlando, A, Scribano, ML, Vecchi, M, Rizzello, F, Ardizzone, S, Armuzzi, A, Castiglione, F, Danese, S, Daperno, M, Fantini, M, Fiorino, G, Frieri, G, Gionchetti, P, Neri, L, Orlando, A, Principi, M, Rizzello, F, Scribano, ML, Sturniolo, GC, Vecchi, M & GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group 2016, 'Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))', Digestive and Liver Disease, vol. 48, no. 9, pp. 1103. https://doi.org/10.1016/j.dld.2016.06.015

@article{2f160547f0ba449dba2387e42312368d,

title = "Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))",

abstract = "In the last paragraph of Section 1, the sentence “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]” should be replaced with: “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]”. Mariabeatrice Principi, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, should have been listed in Appendix A (Members of the GIVI Study Group).",

author = "Alessandro Armuzzi and Paolo Gionchetti and Marco Daperno and Silvio Danese and Ambrogio Orlando and Scribano, {Maria Lia} and Maurizio Vecchi and Fernando Rizzello and Sandro Ardizzone and Alessandro Armuzzi and Fabiana Castiglione and Silvio Danese and Marco Daperno and Massimo Fantini and Gionata Fiorino and Giuseppe Frieri and Paolo Gionchetti and Luca Neri and Ambrogio Orlando and Mariabeatrice Principi and Fernando Rizzello and Scribano, {Maria Lia} and Sturniolo, {Giacomo Carlo} and Maurizio Vecchi and {GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group}",

year = "2016",

month = sep,

day = "1",

doi = "10.1016/j.dld.2016.06.015",

language = "English",

volume = "48",

pages = "1103",

journal = "Digestive and Liver Disease",

issn = "1590-8658",

publisher = "Elsevier B.V.",

number = "9",

}

TY - JOUR

T1 - Erratum

T2 - Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))

AU - Armuzzi, Alessandro

AU - Gionchetti, Paolo

AU - Daperno, Marco

AU - Danese, Silvio

AU - Orlando, Ambrogio

AU - Scribano, Maria Lia

AU - Vecchi, Maurizio

AU - Rizzello, Fernando

AU - Ardizzone, Sandro

AU - Armuzzi, Alessandro

AU - Castiglione, Fabiana

AU - Danese, Silvio

AU - Daperno, Marco

AU - Fantini, Massimo

AU - Fiorino, Gionata

AU - Frieri, Giuseppe

AU - Gionchetti, Paolo

AU - Neri, Luca

AU - Orlando, Ambrogio

AU - Principi, Mariabeatrice

AU - Rizzello, Fernando

AU - Scribano, Maria Lia

AU - Sturniolo, Giacomo Carlo

AU - Vecchi, Maurizio

AU - GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group

PY - 2016/9/1

Y1 - 2016/9/1

N2 - In the last paragraph of Section 1, the sentence “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]” should be replaced with: “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]”. Mariabeatrice Principi, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, should have been listed in Appendix A (Members of the GIVI Study Group).

AB - In the last paragraph of Section 1, the sentence “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]” should be replaced with: “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]”. Mariabeatrice Principi, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, should have been listed in Appendix A (Members of the GIVI Study Group).

UR - http://www.scopus.com/inward/record.url?scp=84986552137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986552137&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2016.06.015

DO - 10.1016/j.dld.2016.06.015

M3 - Comment/debate

SN - 1590-8658

VL - 48

SP - 1103

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

IS - 9

ER -

Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this